Trials / Withdrawn
WithdrawnNCT06113341
A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes
A Multi-centre, Prospective, Single-arm, Non-interventional Study Describing the Use of the Dose Check App in People Living With Type 2 Diabetes Mellitus and Treated With IDegLira in a Real-world Setting in Italy
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This study will look at how a mobile based app called 'Dose Check' used along with Xultophy® helps the treatment in participants with type 2 diabetes mellitus (T2DM). Participants will get Xultophy® as prescribed by study doctor or will continue already prescribed treatment with Xultophy®. Participants will also be prescribed to use Dose Check app by study doctor. Participants will be asked to install the Dose Check app in their mobile phone, which will be supported with the correct dose of Xultophy®. The study will last for about 6 to 8 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IDegLira | Pre-filled pen injection. |
Timeline
- Start date
- 2024-11-07
- Primary completion
- 2025-02-23
- Completion
- 2026-03-02
- First posted
- 2023-11-02
- Last updated
- 2024-10-01
Locations
19 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06113341. Inclusion in this directory is not an endorsement.